Lopinavir/Ritonavir Monotherapy as Second-line Antiretroviral Treatment in Resource-Limited Settings: Week 104 Analysis of AIDS Clinical Trials Group (ACTG) A5230 | Zendy

Nagalingeswaran Kumarasamy | Zendy; Evgenia Aga | Zendy; Heather J. Ribaudo | Zendy; Carole L. Wallis | Zendy; David Katzenstein | Zendy; Wendy Stevens | Zendy; Michael Norton | Zendy; Karin L. Klingman | Zendy; Mina C. Hosseinipour | Zendy; John A. Crump | Zendy; Khuanchai Supparatpinyo | Zendy; Sharlaa BadalFaesen | Zendy; John Bartlett | Zendy

Open Access

Lopinavir/Ritonavir Monotherapy as Second-line Antiretroviral Treatment in Resource-Limited Settings: Week 104 Analysis of AIDS Clinical Trials Group (ACTG) A5230

Author(s) -

Nagalingeswaran Kumarasamy,

Evgenia Aga,

Heather J. Ribaudo,

Carole L. Wallis,

David Katzenstein,

Wendy Stevens,

Michael Norton,

Karin L. Klingman,

Mina C. Hosseinipour,

John A. Crump,

Khuanchai Supparatpinyo,

Sharlaa BadalFaesen,

John Bartlett

Publication year - 2015

Publication title -

clinical infectious diseases

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 3.44

H-Index - 336

eISSN - 1537-6591

pISSN - 1058-4838

DOI - 10.1093/cid/civ109

Subject(s) - lopinavir , medicine , ritonavir , lopinavir/ritonavir , clinical trial , second line , human immunodeficiency virus (hiv) , antiretroviral therapy , first line , virology , viral load

The AIDS Clinical Trials Group (ACTG) A5230 study evaluated lopinavir/ritonavir (LPV/r) monotherapy following virologic failure (VF) on first-line human immunodeficiency virus (HIV) regimens in Africa and Asia.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research